WG
PTCT icon

Winton Group’s PTC Therapeutics PTCT Stock Holding History

Winton Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,668
Closed -$231K – 903
2023
Q2 		$231K Buy
+5,668
New +$277K 0.02% 622
2020
Q1 		– Sell
-11,452
Closed -$550K – 1509
2019
Q4 		$550K Buy
+11,452
New +$487K 0.01% 1217
2019
Q2 		– Sell
-7,197
Closed -$271K – 1256
2019
Q1 		$271K Sell
7,197
-1,567
-18% -$52.6K 0.01% 833
2018
Q4 		$301K Buy
8,764
+2,873
+49% +$103K 0.01% 656
2018
Q3 		$277K Buy
+5,891
New +$244K 0.01% 846

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Winton Group's PTCT Position: Q3 2023 in Review

Winton Group sold out of PTC Therapeutics (PTCT) in Q3 2023, closing a stake of 5,668 shares — an estimated $231K sold.

Winton Group first reported a position in PTCT in Q3 2018 and held it in 5 quarters. The position peaked at $550K in Q4 2019. 179 funds tracked by Wall St. Rank hold PTCT as of Q3 2023.

  • Winton Group reported no remaining PTC Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Winton Group sold 5,668 PTC Therapeutics shares in Q3 2023, an estimated $231K.
  • Winton Group first reported a position in PTC Therapeutics in Q3 2018 and held it in 5 quarters.
  • Winton Group's PTC Therapeutics position peaked at $550K in Q4 2019.
  • 179 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2023.

Based on Winton Group's 13F filing for Q3 2023, filed 13 Nov 2023.